| Microscopic Colitis | Lifetime | 3 | FR 1 | 99.96 |
| Inflammatory Bowel Disease | Lifetime | 4 | FR 1 | 99.96 |
| Autoimmune and Inflammatory Disorders | Lifetime | 2 | FR 1 | 99.96 |
| Biosimilars and Bioanalytical Methods | Lifetime | 3 | FR 1 | 99.78 |
| Eosinophilic Esophagitis | Lifetime | 16 | FR 1 | 99.81 |
| Pregnancy and Medication Impact | Lifetime | 12 | FR 1 | 99.61 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 39 | FR 4 | 99.72 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 105 | FR 2 | 99.41 |
| COVID-19 and healthcare impacts | Lifetime | 78 | FR 2 | 98.25 |
| Diagnosis and treatment of tuberculosis | Lifetime | 42 | FR 1 | 99.25 |
| Diverticular Disease and Complications | Lifetime | 61 | FR 2 | 99.24 |
| Liver Diseases and Immunity | Lifetime | 57 | FR 5 | 99.29 |
| Celiac Disease Research and Management | Lifetime | 45 | FR 3 | 98.97 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 93 | FR 9 | 99.19 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 368 | FR 4 | 98.97 |
| COVID-19 Clinical Research Studies | Lifetime | 644 | FR 36 | 97.68 |
| Mycobacterium research and diagnosis | Lifetime | 406 | FR 27 | 97.95 |
| Pharmaceutical studies and practices | Lifetime | 251 | FR 7 | 97.78 |
| Acute Lymphoblastic Leukemia research | Lifetime | 728 | FR 47 | 97.48 |
| Colorectal Cancer Screening and Detection | Lifetime | 814 | FR 22 | 97.23 |
| Appendicitis Diagnosis and Management | Lifetime | 514 | FR 35 | 95.89 |
| IL-33, ST2, and ILC Pathways | Lifetime | 450 | FR 15 | 95.87 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 691 | FR 32 | 95.10 |
| Adolescent and Pediatric Healthcare | Lifetime | 988 | FR 13 | 93.33 |
| Anorectal Disease Treatments and Outcomes | Lifetime | 904 | FR 57 | 93.08 |
| Inflammation biomarkers and pathways | Lifetime | 571 | FR 36 | 76.73 |
| Inflammatory Bowel Disease | 2021-2025 | 2 | FR 1 | 99.97 |
| Microscopic Colitis | 2021-2025 | 2 | FR 1 | 99.98 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 1 | FR 1 | 99.92 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 3 | FR 1 | 99.55 |
| Eosinophilic Esophagitis | 2021-2025 | 5 | FR 1 | 99.72 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 7 | FR 2 | 99.66 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 8 | FR 1 | 99.41 |
| Pregnancy and Medication Impact | 2021-2025 | 4 | FR 1 | 98.93 |
| Celiac Disease Research and Management | 2021-2025 | 4 | FR 1 | 98.96 |
| Diverticular Disease and Complications | 2021-2025 | 16 | FR 2 | 98.11 |
| Pharmaceutical studies and practices | 2021-2025 | 22 | FR 1 | 97.72 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 129 | FR 3 | 98.26 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 91 | FR 4 | 98.79 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 26 | FR 1 | 96.39 |
| Liver Diseases and Immunity | 2021-2025 | 39 | FR 3 | 98.55 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 112 | FR 6 | 96.98 |
| Colorectal Cancer Screening and Detection | 2021-2025 | 233 | FR 9 | 95.94 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 44 | FR 1 | 94.51 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 267 | FR 16 | 96.21 |
| Gastrointestinal motility and disorders | 2021-2025 | 117 | FR 3 | 95.17 |
| Appendicitis Diagnosis and Management | 2021-2025 | 145 | FR 9 | 91.96 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 143 | FR 3 | 91.88 |
| Mycobacterium research and diagnosis | 2021-2025 | 415 | FR 14 | 89.71 |
| Acute Lymphoblastic Leukemia research | 2021-2025 | 625 | FR 34 | 91.29 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 784 | FR 45 | 90.89 |
| Anorectal Disease Treatments and Outcomes | 2021-2025 | 310 | FR 18 | 87.74 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 860 | FR 44 | 88.56 |
| Adolescent and Pediatric Healthcare | 2021-2025 | 611 | FR 10 | 84.29 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 620 | FR 26 | 87.07 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 359 | FR 10 | 71.42 |
